GGrantIndex
Sort

10,829 grants matching car t

Optimizing CAR T Cell Therapy

$379,293
Bruce R. Blazar · University Of Minnesota · P01 · FY2016 · CA

Optimizing CAR T Cell Therapy

$379,257
Bruce R. Blazar · University Of Minnesota · P01 · FY2017 · CA

Optimizing CAR T Cell Therapy

$379,224
Bruce R. Blazar · University Of Minnesota · P01 · FY2018 · CA

The B7x pathways in the tumor microenvironment

$379,050
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2024 · CA

Improving Technician Training in Battery Technology

$378,987
Robert E Wechsler · Florida State College At Jacksonville · · FY2022 · EDU

Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma

$378,675
Paolo Strati · University Of Tx Md Anderson Can Ctr · R21 · FY2021 · CA

Quantifying the attentional template

$378,611
Joy Jia Geng · University Of California At Davis · R01 · FY2018 · MH

Tumor microenvironment-dependent therapy resistance

$378,600
Shahab Asgharzadeh · Children'S Hosp Of Philadelphia · P01 · FY2024 · CA

Prevention of adenovirus pathogenesis through downregulation of the apical adenovirus receptor

$378,540
Abimbola Olayinka Kolawole · Wright State University · R01 · FY2021 · AI

Age-Related Meibomian Gland Dysfunction

$378,525
James V Jester · University Of California-Irvine · R01 · FY2014 · EY

Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code

$378,416
Han Xiao · Rice University · R35 · FY2023 · GM

Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code

$378,416
Han Xiao · Rice University · R35 · FY2021 · GM

Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code

$378,416
Han Xiao · Rice University · R35 · FY2022 · GM

Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

$378,389
Mark S Berger · Actinium Pharmaceuticals, Inc. · R42 · FY2020 · CA

Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML

$378,249
Jeffrey S Miller · University Of Minnesota · P01 · FY2024 · CA

Smartphone-based diagnostic for HIV self-testing

$378,111
Jacqueline Linnes · Purdue University · R61 · FY2019 · AI

SBIR Phase II: Revenue Management in a Dynamic and Stochastic Network Environment

$378,101
Georgia Mourtzinou · Dynamic Ideas, Llc · · FY2001 · TIP

Effects of circadian desynchrony during adolescent alcohol exposure on immediate and long-term risk of alcohol addiction: role of sleep homeostasis and stress signaling

$378,095
Danielle Gulick · University Of South Florida · R01 · FY2023 · AA

Linking Process-Induced Properties to Thermoplastic-Matrix Woven-Fabric Composites Performance

$378,000
James Sherwood · University Of Massachusetts Lowell · · FY2005 · ENG

The B7x pathways in the tumor microenvironment

$378,000
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2024 · CA

Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response

$377,999
Mercedes R. Rincon · University Of Colorado Denver · R01 · FY2022 · CA

Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response

$377,999
Mercedes R. Rincon · University Of Colorado Denver · R01 · FY2025 · CA

Neural mechanisms mediating visual search

$377,953
Robert Desimone · Massachusetts Institute Of Technology · R01 · FY2013 · EY

Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris

$377,457
Aimee S Payne · Columbia University Health Sciences · R01 · FY2025 · AR

Mechanisms of Enterovirus Entry

$377,425
Susan Hafenstein · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2019 · AI